Preview

Антибиотики и Химиотерапия

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Современное состояние профилактики и лечения лихорадки Чикунгунья

https://doi.org/10.37489/0235-2990-2020-65-3-4-45-53

Полный текст:

Аннотация

Вирус Чикунгунья (CHIKV) — это альфа-вирус, передаваемый людям комарами Aedes, традиционно Aedes aegypti и Aedes albopictus. Вирус вызывает лихорадку Чикунгунья — болезнь, которая характеризуется лихорадкой, тошнотой, головны­ми болями, сыпью и стойкой артралгией. Лихорадка Чикунгунья может быть связана с тяжёлыми осложнениями, вклю­чая смерть. С 2005 г. CHIKV распространяется по всему миру, что приводит к эпидемиям в Африке, островах Индийско­го океана, Азии и совсем недавно в Северной и Южной Америке. Глобально расширяющиеся пандемии с ревматическими расстройствами CHIKV и постинфекционными осложнениями усиливают проблемы общественного здравоохранения. Для лечения этой вирусной инфекции не существует конкретной вакцины или лекарственного средства. Анализ поиска эффек­тивных в отношении CHIKV препаратов показал, что, несмотря на разнообразие направлений исследований, использова­ние современных достижений в молекулярной биологии, нет одобренных и принятых для использования в практической медицине ни этиотропных средств лечения, ни МИБП. Вместе с тем внушают оптимизм новые стратегии в области про­тивовирусных исследований. Комбинированная химиотерапия с интерферонами и противовирусными агентами является привлекательной терапевтической стратегией для обеспечения повышенной противовирусной активности и снижения концентраций препаратов.

Об авторах

С. Я. Логинова
ФГБУ «48 Центральный научно-исследовательский институт» Министерства обороны Российской Федерации»
Россия
Сергиев Посад


В. Н. Щукина
ФГБУ «48 Центральный научно-исследовательский институт» Министерства обороны Российской Федерации»
Россия
Сергиев Посад


С. В. Борисевич
ФГБУ «48 Центральный научно-исследовательский институт» Министерства обороны Российской Федерации»
Россия
Сергиев Посад


Список литературы

1. Salata C, Calistri A, Parolin C., et al. Antiviral activity of cationic amphiphilic drugs Expert Rev Anti Infect Ther 2017; 20: 1—10.

2. Wang Y.M., Lu J.W., Lin C.C. et al. Antiviral activities of niclosamide and nitazoxanide against Chikungunya virus entry and transmission. Antiviral Res 2016; 135: 81-90.

3. Delang L, Li C, Tas A. et al. The viral capping enzyme nsP1: a novel target for the inhibition of Chikungunya virus infection. Sci Rep 2016; 6: 31819.

4. Ching K.C., Kam Y.W., Merits A. et al. Trisubstituted Thieno[3,2-b]pyr- role 5-Carboxamides as Potent Inhibitors of Alphaviruses. J Med Chem 2015; 58 (23): 9196-9213.

5. Gigante A., Gomez-SanJuan A., Delang L. et al. Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones against Chikungunya virus targeting the viral capping nsP1. Antiviral Res. 2017; 144: 216-222.

6. Abdelnabi R, Neyts J., Delang L., Abdelnabi, R. Towards antivirals against Chikungunya virus. Antivir Res 2015; 121: 59-68.

7. Abdelnabi R, Neyts J., Delang L. Chikungunya virus infections: time to act, time to treat. Curr Opin Virol 2017; 24: 25-30.

8. Lani R., Hassandarvish P., Shu M.-H. et al. Antiviral activity of selected flavonoids against Chikungunya virus. Antivir Res 2016; 133: 50-61.

9. Albulescu I.C., van Hoolwerff M., Wolters L.A. et al. Suramin inhibits Chikungunya virus replication through multiple mechanisms. Antivir Res 2015; 121: 39-46.

10. Mishra P., Kumar A., Mamidi P. et al. Inhibition of Chikungunya virus replication by 1-[(2-Methylbenzimidazol-1-yl) methyl]-2-oxo-indolin- 3-ylidene] amino] thiourea(MBZM-N-IBT). Sci Rep 2016; 6: 20122.

11. Varghese S., Thaa B., Amrun S.N. et al. The antiviral alkaloid berberine reduces Chikungunya virus-induced mitogen-activated protein kinase signaling. J Virol 2016; 90: 9743-9757.

12. Cotin S., Calliste C.-A., Mazeron M.-C. et al. Eight flavonoids and their potential as inhibitors of human cytomegalovirus replication. Antiviral Research 2012; 96 (2): 181-186.

13. Moghaddam E., Teoh B.-T., Sam S.-S. et al. Baicalin, a metabolite of baicalein with antiviral activity against dengue virus. Scientific Reports 2014; 4: 5452.

14. Ahmadi A., Hassandarvish P., Lani R. et al. Inhibition of Chikungunya virus replication by hesperetin and naringenin. RSC Advances 2016; 6: 69421-69430.

15. Oo D.,Hassandarvish P., Chin S. P. et al. In silico study on anti- Chikungunya virus activity of hesperetin. Peer J 2016; 4: e2602.

16. Henfi L, Beck S, Weidner T. et al. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry. Virol J 2016; 13: 149.

17. Mitsuya H, Popovic M., Yarchoan R. et al. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science. 1984; 226: 172-174.

18. Yahi N., Sabatier J.M., Nickel P. et al. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J Biol Chem 1994; 269: 24349-24353.

19. Aguilar H.C., Anderson W.F., Cannon P.M. Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide J Virol 2003; 77: 1281-1291.

20. Kessler H.A., Pottage J.C., Trenholme G.M. et al. Effects of suramin on in vitro HBsAg production by PLC PRF 5 cells and hepatitis B virus DNA polymerase activity. AIDS Res 1986; 2: 63-72.

21. Garson J.A., Lubach D., Passas J. et al. Suramin blocks hepatitis C binding to human hepatoma cells in vitro. J. Med. Virol. 1999; 57: 238-242.

22. Basavannacharya C., Vasudevan S.G. Suramin inhibits helicase activity of NS3 protein of dengue virus in a fluorescence-based high throughput assay format. Biochem Biophys Res Commun 2014; 453: 539-544.

23. Wang Y., Qing J., Sun Y., Rao Z. Suramin inhibits EV71 infection Antivir Res 2014; 103: 1-6.

24. Ellenbecker M., Lanchy J.-M., Lodmell J.S. Inhibition of Rift Valley fever virus replication and perturbation of nucleocapsid-RNA interactions by suramin. Antimicrob Agents Chemother 2014; 58: 7405-7415.

25. Ho Y.-J., Wang Y.-M., J.-W. Lu J.-W. et al. Suramin Inhibits Chikungunya Virus Entry and Transmission. PLoS One. 2015; 10: e0133511.

26. Kuo S.C., Wang Y.M., Ho Y.J. et al. Suramin treatment reduces chikun- gunya pathogenesis in mice. Antiviral Res 2016; 134: 89-96.

27. Hwu J.R., Gupta N.K., Tsay S.C. et al. Bis(benzofuran-thiazolidinone)s and bis(benzofuran-thiazinanone)s as inhibiting agents for Chikungunya virus. Antiviral Res 2017; 146: 96-101.

28. Nothias-Scaglia L.F., Pannecouque C., F. Renucci F. et al. Antiviral activity of diterpene esters on Chikungunya virus and HIV replication. J Nat Prod 2015; 78 (6): 1277-1283.

29. Aggarwal M., Kaur R., Saha A. et al. Evaluation of antiviral activity of piperazine against Chikungunya virus targeting hydrophobic pocket of alphavirus capsid protein. Antiviral Res 2017; 146: 102-111.

30. Crance J.M., Scaramozzino N., Jouan A., Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003; 58 (1): 73-79.

31. Briolant S., Garin D., Scaramozzino N. et al. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 2004; 61 (2): 111-117.

32. Leyssen P., de Clercq E., Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Molecular Pharmacology. 2006; 69(4): 1461-1467.

33. Lamballerie X., Ninove L., Charrel R.N. Antiviral treatment of Chikungunya virus infection. Infectious Disorders — Drug Targets 2009; 9 (2): 101-104.

34. Rada B., Dragun M. Antiviral action and selectivity of 6 azauridine. Ann New York Acad Sci 1977; 284: 410-417.

35. Preston S.L.,Drusano G.L., Glue P. et al. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999; 43: 2451-2456.

36. Ravichandran R., Manian M. Ribavirin therapy for Chikungunya arthritis. J Infect Develop Countr 2008; 2: 2: 140-142.

37. Caglioti C., Lalle E., Castilletti C. et al. Chikungunya virus infection: an overview. New Microbiol 2013; 36: 211-227.

38. Brehin A.-C., Casademont I., Frenkiel M.-P. et al. The large form of human 2’,5’-Oligoadenylate Synthetase (OAS3) exerts antiviral effect against Chikungunya virus. Virology 2009; 384 (1): 216-222.

39. Gad H., Paulous S., Belarbi E. et al. The E2-E166K substitution restores Chikungunya virus growth in OAS3 expressing cells by acting on viral entry. Virology 2012; 434 (1): 27-37.

40. Varghese F.S., Thaa B., Amrun S.N. et al. The antiviral alkaloid berberine reduces Chikungunya virus-induced mitogen-activated protein kinase signaling. J Virol 2016; 90: 9743-9757.

41. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res 2005; 107: 165-171.

42. Gallegos K.M., Drusano G.L., Argenio D.Z.D, Brown A.N. Chikungunya virus: In Vitro response to combination therapy with ribavirin and interferon alfa 2a. J Infect Dis 2016; 214 (8): 1192-1197.

43. Scagnolari C., Caputo B., Rezza G., Antonelli G. Antiviral activity of the combination of interferon and ribavirin against Chikungunya virus: Are the Results Conclusive? Infect Dis 2017; 215 (3): 492-493.

44. Delang L., Segura Guerrero N., Tas A. et al. Mutations in the Chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 2014; 69 (10): 2770-2784.

45. Bassetto M., de Burghgraeve T., Delang L. et al. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against Chikungunya virus. Antiviral Research 2013; 98 (1): 12-18.

46. Parashar D., Cherian S. Antiviral perspectives for Chikungunya virus. Biomed Res Int 2014; 631-642.

47. Gigante A., Gomez-SanJuan A., Delang L. et al. Antiviral activity of [1,2,3]triazolo[4,5- d]pyrimidin-7(6 H)-ones against Chikungunya virus targeting the viral capping nsP1. Antiviral Res 2017; 144: 216-222.

48. Ehteshami M., Tao S., Zandi K. et al. Characterization of /З-d- N 4- Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. Antimicrob. Agents Chemother 2017; 61(4): e02395-16.

49. Delogu I., Pastorino B., Baronti C. et al. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 2011; 90 (3): 99-107.

50. Kaur V, Thiruchelvan M., Lee R.C.H. et al. Inhibition of Chikungunya virus replication by Harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother 2013; 57 (1): 155.

51. Dash P.K., Tiwari M., Santhosh S.R. et al. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophysic Res Commun 2008; 376 (4): 718-722.

52. Parashar D., Paingankar M.S., Kumar S. et al. Administration of E2 and NS1 siRNAs inhibit Chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Neglected Tropical Diseases 2013; 7 (9): e2405.

53. Couderc T, Khandoudi N, Grandadam M. et al. Prophylaxis and therapy for Chikungunya virus infection. Journal of Infectious Diseases. 2009; 200 (4): 516-523.

54. Suhrbier A. Arthritogenic alphaviruses-an overview A. Suhrbier, M.C. Jaffar-Bandjee, P.Gasque Nature Reviews. Rheumatology. 2012; 8 (7): 420-429.

55. Harrison V.R., Binn L.N., Randall R. Comparative immunogenicities of Chikungunya vaccines prepared in avian and mammalian tissues. Am J Tropical Med Hygiene 1967; 16 (6): 786-791.

56. White A., White A., Berman S, Lowenthal J.P. Comparative immunogenicities of Chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures. App Microbiol 1972; 23 (5): 951-952.

57. EckelsK.H., Harrison V.R., HetrickF.M.Chikungunya virus vaccine prepared by Tween-ether extraction. App Microbiol 1970; 19 (2): 321-325.

58. Nakao E, Hotta S. Immunogenicity of purified, inactivated Chikungunya virus in monkeys. Bull World Health Organizat 1973; 48 (5): 559-562.

59. Gardner J., Anraku I., Le T.T. et al. Chikungunya virus arthritis in adult wild-type mice. J Virology 2010; 84 (16): 8021-8032.

60. Plante K., WangE, Partidos C.D. et al. Novel Chikungunya vaccine candidate with an ires-based attenuation and host range alteration mechanism. PLoS Pathogens. 2011; 7 (7): e1002142.

61. Wang E, Volkova E., Adams A.P. et al. Chimeric alphavirus vaccine candidates for Chikungunya. Vaccine. 2008; 26(39): 5030-5039.

62. Mallilankaraman K., Shedlock D.J., Bao H. et al. A DNA vaccine against Chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Neglected Trop Dis 2011; 5 (1): e928.

63. Szabo T.G., Palotai R., Antal P. et al. Critical role of glycosylation in determining the length and structure of T cell epitopes. Immunome Res 2009; 5 (1): 4.

64. Wang D., Suhrbier A., Penn-Nicholson A. et al. A complex adenovirus vaccine against Chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011; 29 (15): 2803-2809.

65. Kumar M., Sudeep A.B., Arankalle V.A. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against Chikungunya virus. Vaccine 2012; 30 (43): 6142-6149.

66. Kramer R.M., Zeng Y., Sahni N. et al. Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation ofthe effects of polyanions. J Pharm Sci 2013; 102 (12): 4305-4314.

67. Khan M., Dhanwani R., Rao P.V. et al. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1 Th2 response and virus-neutralizing antibodies in mice. Virus Research 2012; 167 (2): 236-246.

68. Chu H., Das S.C., Fuchs J.F. et al. Deciphering the protective role of adaptive immunity to CHIKV IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 2013; 31 (33): 3353-3360.


Для цитирования:


Логинова С.Я., Щукина В.Н., Борисевич С.В. Современное состояние профилактики и лечения лихорадки Чикунгунья. Антибиотики и Химиотерапия. 2020;65(3-4):45-53. https://doi.org/10.37489/0235-2990-2020-65-3-4-45-53

For citation:


Loginova S.J., Shchukina V.N., Borisevich S.V. The Modern State of Prevention and Treatment of Chikungunya Fever. Antibiotics and Chemotherapy. 2020;65(3-4):45-53. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-3-4-45-53

Просмотров: 98


ISSN 0235-2990 (Print)